A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis.
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2015
At a glance
- Drugs AMG 811 (Primary)
- Indications Glomerulonephritis; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Amgen
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 14 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 15 May 2014 Planned End Date changed from 1 Jul 2014 to 1 Aug 2014 according to ClinicalTrials.gov record.